After Johnson & Johnson's consumer healthcare spinoff last year—and its subsequent reduction in holdings in the new company—the healthcare conglomerate is once again cutting its stake in Kenvue.
Johnson & Johnson plans to unload its remaining 9.5% stake in Kenvue in a public offering set about a year after it started splitting off the Tylenol and Benadryl maker. Kenvue said Monday that it ...
Some results have been hidden because they may be inaccessible to you